Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 3/20 | 0.55 |
| ▸ | YARS1 | P54577 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | CPA1 | P15085 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887814 | 1.00 | SLC7A5 (0.58) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL5887796 | 1.00 | SLC7A5 (0.58) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL30439955 | 0.94 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL27653020 | 0.94 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL1574161 | 0.94 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL1574158 | 0.94 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL31025673 | 0.94 | SLC7A5 (0.65) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL30839475 | 0.92 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL678159 | 0.92 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 | |
| SCHEMBL678158 | 0.92 | SLC7A5 (0.61) | SLC7A5MMEYARS1ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995238-B2 | Cyclopeptide derivatives | BIOMET DEUTCHLAND GMBH (DE) | 2006-02-07 | — | — | US | disclosed |
| EP-1037906-B1 | CYCLOPEPTIDE DERIVATIVES WITH INTEGRIN INHIBITOR PROPERTIES | BIOMET DEUTSCHLAND GMBH (DE) | 2005-02-16 | — | — | EP | disclosed |
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6610826-B1 | Useful for treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis | MERCK PATENT DEPARTMENT (DE) | 2003-08-26 | — | — | US | disclosed |
| CN-1118475-C | Cyclopeptide derivatives | MERCK PATENT GMBH (DE) | 2003-08-20 | — | — | CN | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020198142-A1 | Cyclopeptide derivatives | MERCK PATENT GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| CN-1282337-A | Cyclopeptide derivatives with integrin inhibitor properties | MERCK PATENT GMBH (DE) | 2001-01-31 | — | — | CN | disclosed |
| EP-1037906-A1 | CYCLOPEPTIDE DERIVATIVES WITH INTEGRIN INHIBITOR PROPERTIES | MERCK PATENT GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031126-A1 | CYCLOPEPTIDE DERIVATIVES WITH INTEGRIN INHIBITOR PROPERTIES | MERCK PATENT GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| CN-1202907-A | Cyclopeptide derivatives | MERCK PATENT GMBH (DE) | 1998-12-23 | — | — | CN | disclosed |
| EP-0771818-A2 | Biotin derivatives | MERCK PATENT GmbH (DE) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198142-A1 | Cyclopeptide derivatives | COL2A1, SRRM2, ARGLU1 | SLC7A5 2637/4885MME 1379/4885YARS1 2387/4885 |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | SLC7A5 2879/4885MME 3084/4885YARS1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.